Skip to main content
Equibles
GALT logo

GALT · Galectin Therapeutics Inc

Track GALT — free

Use GALT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GALT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.90 +0.14 (+3.72%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$393.31M
Shares
100.85M
Volume · Oct 2 220.51K Avg daily vol (3M) 394.37K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.90 Open$3.82 Day$3.75–3.94 52W close$2.08–6.51 Avg vol 30d301K Short int9.3M · 9.3% float · 25.2d Short vol51% Last earningsAug 14, 2025 DataJan 2020–Oct 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$27.84M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$13.27M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.8%
Year over year · more shares
Price change (1Y)
-8.2%
Trailing year
Short interest
9.3%
Latest settlement · 25.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +19%
above
Price vs 50-day avg +5%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 41%
mid-range
Momentum
relative strength
Neutral
1-month return −10%
trailing
6-month return +66%
trailing
YTD return −6%
this year
Relative strength +54%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.26% of float · ▲ +2.9% MoM · 25.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
101 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Fair
EPS growth +37%
Y/Y
Free cash flow $-23.9M
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −68%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+19% Bullish
Price vs 50-day avg
+5% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
41% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.26% of float · ▲ +2.9% MoM · 25.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
101 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $4 · 41% Range high $7
vs 200-day avg +19% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GALT
Galectin Therapeutics Inc
this stock
$393.31M -6.3% — — 9.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
101
% held
16.9%
Net QoQ
+1.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
68
View
Short & Settlement
Short Interest Rising
Shares short
9.3M
Days to cover
25.2d
Change
+259.9K sh
View
Short Volume
Short vol %
51%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
11.8K
Value
$46.0K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
42.6%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-30.8M
EPS diluted
$-0.48
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
11
View
Proposed Sales
Value
$341.4K
Shares
68.3K
Filed
Jun 26, 2026
View
Earnings & Events
Webcasts
Last webcast
Mar 10, 2026
View

Performance

5D 20D 120D MTD YTD
GALT +0.0% -10.3% +66.0% +0.5% -6.3%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY +0.2% -9.9% +53.8% -0.4% -19.1%
Key facts CIK 1133416 CUSIP 363225202 13F (30d) 2 filings 2 filers Visit website